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Epidemiological studies aim at assessing the relationship
between exposures and outcomes. Clinicians are interested
in knowing not only whether a link between a given
exposure (e.g. smoking) and a certain outcome (e.g.
myocardial infarction) is statistically significant, but also the
magnitude of this relationship. The ‘measures of effect’ are
indexes that summarize the strength of the link between
exposures and outcomes and can help the clinician in taking
decisions in every day clinical practice. In epidemiological
studies, the effect of exposure can be measured both in
relative and absolute terms. The risk ratio, the incidence rate
ratio, and the odds ratio are relative measures of effect. Risk
difference is an absolute measure of effect and it is calculated
by subtracting the risk of the outcome in exposed individuals
from that of unexposed.
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This study addresses the measures of effect, that is, the
measures that are used to compare the frequency of disease
(or other outcome) between two groups. The measures of
effect are generally expressed as relative risks and odds ratios
(OR) (relative measures of effect) or as risk difference
(absolute measure of effect). The ‘number needed to treat’
(NNT) is another absolute measure of effect that is frequently
used in clinical trials.
RELATIVE MEASURES OF EFFECT
The relative risk
The relative risk can be calculated as ratio between two
incidence proportions (risk ratio, see Example 1) or two
incidence rates (incidence rate ratio, see Example 2).
Example 1: In the randomized prospective, Heart Out-
comes Prevention Evaluation (HOPE) study,1 the effect of
ramipril on the risk of cardiovascular (CV) events, was
investigated by calculating the ratio between the incidence
proportions of CV events in ramipril-treated and in placebo-
treated patients.
A value of 0.78 indicates that patients treated with ramipril
had a lower risk than untreated patients and that this drug
induced a 22% decrease in the risk of CV events (relative risk
reduction).
The confidence interval
The risk ratio (as well as other measures of effect) is generally
accompanied by a measure of the precision of the estimate:
the confidence interval (CI). In the HOPE study, the CI was
0.70–0.86. The concept of the CI can be explained as follows:
if 100 samples of the same size considered in the HOPE study
would be drawn from the population and if we would
calculate for each sample the risk ratio associated with
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With CV
events
Without CV
events
Ramipril group (n=4645) 651 3994
Placebo group (n=4652) 826 3826
Proportion of patients with CV events in the ramipril group: 651/4645=0.14 (14%).
Proportion of patients with CV events in the placebo group: 826/4652=0.18 (18%).
The risk ratio is 0.14/0.18=0.78.
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ramipril treatment, we would obtain a 100 (all slightly
different) risk ratio estimates. The 95% CI is the interval that
includes the 95% of risk ratios of these 100 population
samples. Thus, the 95% CI is the interval of values in which
the true risk ratio is likely to lie with a probability of 95%.
To be statistically significant with a Po0.05, a risk ratio
should have a 95% CI not including 1.0. Thus, in the
HOPE study, the risk ratio of 0.78 (95% CI 0.70–0.86) is
statistically significant.
Example 2: Parekh et al.2 investigated the risk of new
atherosclerotic complications according to race in a prevalent
population of end-stage renal disease patients. They reported
the relative risk for peripheral vascular disease in white as
compared to black dialysis patients in terms of incidence rate
ratio.
The incidence rate ratio is defined as the incidence rate of
disease occurrence in the exposed group divided by the
incidence rate of disease occurrence in the unexposed group
(the calculation of incidence rate is reported in the first paper
of this series).3 In the Parekh’s study, the incidence rate ratio
was calculated as: 114/109¼ 1.05 (95% CI 0.95–1.16). Thus,
in this sample, white dialysis patients have an incidence rate
of peripheral vascular disease that is 5% higher than that in
blacks, but this excess risk did not attain the formal statistical
significance (the 95% CI included 1.0). A 95% CI including 1
means that there is not sufficient, probabilistic evidence that
the excess risk for peripheral vascular diseases in whites than
in blacks is true, in the universe of patients, with a 95%
probability (i.e. there is a probability 45% that this effect is
due to random error, i.e. the error purely attributable to
chance).
The odds ratio
The odds are a way of representing probability, familiar to
gamblers. For example, the odds that a single throw of a die
produces a six are 1–5, that is 1 chance of success and 5
chances of failure (see Example 3). In a case–control study,
the odds of exposure in cases and controls are calculated as
the number of exposed individuals divided by the number of
unexposed individuals in each group. If we know the odds of
exposure in cases and controls, we can calculate the OR, that
is the ratio between the odds of exposure in diseased and in
non-diseased individuals. As discussed for the risk ratio, an
ORo1.0 implies that the risk of the outcome is lower in
exposed individuals than in unexposed individuals; vice versa
an OR41.0 means that the odds are higher in exposed
individuals.
Example 3: Knoll et al.4 investigated the association
between vascular access thrombosis and thrombophilia. They
considered 107 patients with access thrombosis (cases) and
312 patients without fistula thrombosis (controls). Overall,
among the 107 patients with access thrombosis, 59 had
evidence of thrombophilia and 48 did not, while among the
312 without access thrombosis 122 had thrombophilia and
190 did not.
K Odds of thrombophilia in patients with vascular access
thrombosis: 59/48¼ 1.229.
K Odds of thrombophilia in patients without vascular
access thrombosis: 122/190¼ 0.642
The OR is 1.229/0.642¼ 1.91.
An odds ratio of 1.91 means that the odds of exposure to
thrombophilia were 91% higher in patients with vascular
access thrombosis than in those without this complication.
This OR was statistically significant because the 95% CI of
this estimate (95% CI 1.23–2.98) did not include 1. The
authors concluded that although large, multicenter, prospec-
tive cohort studies are needed to confirm this observation,
thrombophilia seems to be associated with vascular access
thrombosis in hemodialysis patients.
To understand why the risk ratio is not appropriate in the
Knoll’s study, we consider the example reported in Figure 1,
showing that, unlike the OR, the risk ratio among others
depends on the number of controls taken for each case. As
shown in Figure 1 (left panel), the risk ratio for arteriovenous
fistula thrombosis results to be 65% higher (risk ratio¼ 1.65)
in patients with thrombophilia than in those without this
complication. Now, as an example, we consider the following
hypothetical situation. If, to increase the study power, the
Incidence rate of peripheral vascular disease
(Events/1000 person-years)
Whites 114
Blacks 109
With
AV fistula
thrombosis
Without
AV fistula
thrombosis
Yes 59 122 59+122=181
48+190=23819048No
Th
ro
m
bo
ph
ilia
OR=(59/48)/(122/190)=1.91
Risk ratio=(59/181)/(48/238)=1.65
With
AV fistula
thrombosis
Without
AV fistula
thrombosis
Yes 59 244 59+244=303
48+380=42838048No
OR=(59/48)/(244/380)=1.91
Risk ratio=(59/303)/(48/428)=1.77
Figure 1 | Left panel: Schematic representation of the Knoll’s study.4 Right panel: by starting with the Knoll’s study we created a
hypothetical situation in which only the number of controls was doubled. As shown in the figure, on changing the number of controls the risk
ratio increases from 1.65 to 1.77, while the OR remains unchanged. The gray area identifies controls.
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investigator had decided to double the number of controls,
hypothesizing that the exposure in this larger control group
remains the same of that of the original control group, the
risk ratio would have increased from 1.65 to 1.77 (!)
(Figure 1, right panel). In contrast, the OR did not change
in respect to the risk ratio (Figure 1). This is because of the
way the two measures of effect are calculated. In fact, the
incidence proportion (by which we calculate the risk ratio) is
dependent on the number of both cases and controls and
exposed and unexposed individuals while the odds, being a
within-group absolute risk indicator, is only affected by the
distribution of exposure in each group. Since the allocation
fraction of the exposure in the larger control group did not
change in respect to the original control group, the OR
remained unchanged. OR is a good estimate of risk ratio
when the disease/event is rare (rare disease assumption).5
ABSOLUTE MEASURES OF EFFECT
Risk difference (or absolute risk reduction)
The effect associated to a specific treatment can be also
calculated in terms of absolute risk difference. The calculation
is just the difference between the incidence proportion of a
disease/event in the control group and the incidence propor-
tion of the same outcome in the treated group. Accordingly, in
the HOPE study, the risk difference for CV events between
patients on placebo and on ramipril is: 0.18–0.14¼ 0.04 (i.e.
4% absolute risk difference attributable to ramipril).
NNT
On the basis of the risk difference it is possible to calculate
the NNT to prevent one adverse event. In the HOPE study,
the number of patients to be treated to prevent one CV event
in 5 years can be calculated as the inverse of the absolute risk
difference (NNT¼ 1/absolute risk difference): 1/0.04 is 25.
So, we ought to treat 25 patients with ramipril to prevent one
CV event in 5 years. The ideal NNT for a given treatment is 1.
In fact a NNT¼ 1 means that all treated individuals had
a favorable outcome (i.e. had no events: incidence
proportion¼ 0), while all untreated individuals had adverse
outcome (i.e. experienced the event in question: incidence
proportion¼ 1). If the number of events in the HOPE study
had been 65 in ramipril group and 83 in placebo group
(instead of 650 and 826, respectively), the NNT would have
been 1/(0.018–0.014)¼ 250, while the RR would have
remained unchanged (RR¼ 0.014/0.018, i.e. 0.78). Thus,
the NNT provides a good insight into the clinical relevance of
the effect.
CONCLUSION
To estimate the magnitude of the association between
exposure and outcomes we can use relative and absolute
measures of effect. Relative measures of effect are risk ratio
(i.e. the ratio between two incidence proportions), incidence
rate ratio (the ratio between two incidence rates), and OR
(the ratio between two odds). The risk difference is an
absolute measure of effect (i.e. the risk of the outcome
in exposed individuals minus the risk of the same outcome in
unexposed). The risk difference is frequently used in clinical
trials to calculate the NNT, that is the number of individuals
that is needed to treat to prevent one adverse event in a given
time period.
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